Rhodes Pharms Drug Patent Portfolio
Rhodes Pharms owns 2 orange book drugs protected by 18 US patents Given below is the list of Rhodes Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis | 09 Nov, 2020 | Expired |
| US10039719 | Methods of treating attention deficit hyperactivity disorder | 16 Jun, 2020 | Expired |
| US6419960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US7083808 | Controlled/modified release oral methylphenidate formulations | 16 Jun, 2020 | Expired |
| US7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US8580310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US9066869 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US9801823 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Jun, 2020 | Expired |
| US10039719 | Methods of treating attention deficit hyperactivity disorder | 16 Dec, 2019 | Expired |
| US10463624 | Controlled release formulations | 16 Dec, 2019 | Expired |
| US6419960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
| US7083808 | Controlled/modified release oral methylphenidate formulations | 16 Dec, 2019 | Expired |
| US7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
| US7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
| US8580310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
| US9066869 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
| US9801823 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | 16 Dec, 2019 | Expired |
Latest Legal Activities on Rhodes Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Rhodes Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 11 Dec, 2023 | US10463624 |
|
Expire Patent
Critical
| 07 Aug, 2023 | US9066869 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Aug, 2023 | US9248229 |
|
Maintenance Fee Reminder Mailed
Critical
| 26 Jun, 2023 | US10463624 |
|
Maintenance Fee Reminder Mailed
Critical
| 20 Feb, 2023 | US9066869 (Litigated) |
|
Expire Patent
Critical
| 12 Sep, 2022 | US10039719 |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Mar, 2022 | US10039719 |
|
Expire Patent
Critical
| 06 Dec, 2021 | US9801823 |
|
Maintenance Fee Reminder Mailed
Critical
| 21 Jun, 2021 | US9801823 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Apr, 2021 | US8580310 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2021 | US9731082 |
|
Expire Patent
Critical
| 23 Nov, 2020 | US7438930 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jun, 2020 | US7438930 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Nov, 2019 | US10463624 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Nov, 2019 | US10463624 |
Rhodes Pharms's Family Patents
Rhodes Pharms Drug List
Given below is the complete list of Rhodes Pharms's drugs and the patents protecting them.
1. Aptensio Xr
Aptensio Xr is protected by 17 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039719
(Pediatric)
| Methods of treating attention deficit hyperactivity disorder |
16 Jun, 2020
(4 years ago)
| Expired |
| US6419960
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US7083808
(Pediatric)
| Controlled/modified release oral methylphenidate formulations |
16 Jun, 2020
(4 years ago)
| Expired |
| US7247318
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US7438930
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US8580310
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US9066869
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US9801823
(Pediatric)
| Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Jun, 2020
(4 years ago)
| Expired |
| US10039719 | Methods of treating attention deficit hyperactivity disorder |
16 Dec, 2019
(4 years ago)
| Expired |
| US10463624 | Controlled release formulations |
16 Dec, 2019
(4 years ago)
| Expired |
| US6419960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
| US7083808 | Controlled/modified release oral methylphenidate formulations |
16 Dec, 2019
(4 years ago)
| Expired |
| US7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
| US7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
| US8580310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
| US9066869 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
| US9801823 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
16 Dec, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptensio Xr's drug page
2. Dilaudid
Dilaudid is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List